Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 9,914 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Active, not recruiting Phase 2 Interventional

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT06092333
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
VIR-2218 and peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 12:41 AM EDT
Recruiting Early Phase 1 Interventional

Fecal Microbiota Transplant for Patients With Chronic Pouchitis

NCT05829109
View directory record Official record
Conditions
Chronic Pouchitis, Pouchitis
Interventions
Fecal Microbiota Transplant (FMT)
Drug
Lead sponsor
Maia Kayal
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

NCT03089944
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 1 Interventional Results available

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987
View directory record Official record
Conditions
Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 27, 2026, 12:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

NCT04548648
View directory record Official record
Conditions
Central Nervous System Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

NCT01200485
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rasburicase, Allopurinol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 27, 2026, 12:41 AM EDT
Not listed Not applicable Interventional

Cerebral Palsy Upper Extremity Orthotic Device

NCT05024409
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Upper Extremity Orthotic, Occupational Therapy
Device · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
4 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Newark, New Jersey • Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 1 Interventional

Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease

NCT00056355
View directory record Official record
Conditions
Crohn Disease
Interventions
UVADEX and UVAR XTS Photopheresis System
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Diabetes Prevention Program Pilot

NCT04651816
View directory record Official record
Conditions
Pre-diabetes
Interventions
Financial Incentives, Motivational Message, DPP Program
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 1 Interventional

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

NCT02620800
View directory record Official record
Conditions
Metastatic Pancreas Adenocarcinoma
Interventions
5FU, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Internet-Based Osteoarthritis Pain Coping Skills Intervention

NCT01638871
View directory record Official record
Conditions
Osteoarthritis
Interventions
PainCOACH
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Smithfield, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

NCT00002734
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
recombinant interferon alfa, chemotherapy, paclitaxel, topotecan hydrochloride, lutetium Lu 177 monoclonal antibody CC49, yttrium Y 90 monoclonal antibody CC49
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 27, 2026, 12:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

NCT05420064
View directory record Official record
Conditions
BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation, POLE Gene Mutation, APC Gene Mutation, ATM Gene Mutation, MLH1 Gene Mutation, BARD1 Gene Mutation, MSH2 Gene Mutation, BRIP1 Gene Mutation, MSH6 Gene Mutation, CHEK2 Gene Mutation, PMS2 Gene Mutation, PALB2 Gene Mutation, EPCAM Gene Mutation, RAD51C Gene Mutation, BMPR1A Gene Mutation, RAD51D Gene Mutation, SMAD4, PTEN Gene Mutation, GREM1
Interventions
Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

NCT00685698
View directory record Official record
Conditions
Diabetic Foot Infections
Interventions
TG-873870 (Nemonoxacin)
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Montebello, California • Pasadena, California • Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

ECAP-controlled, Closed-loop Stimulation to Treat Chronic Trunk and/or Limb Pain (ECAP)

NCT04319887
View directory record Official record
Conditions
Chronic Pain, Back Pain, Pain
Interventions
Evoke Spinal Cord Stimulation (SCS) System
Device
Lead sponsor
Saluda Medical Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Little Rock, Arkansas • Carlsbad, California • Santa Rosa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 27, 2026, 12:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Enhanced Auto-Diagnostic Adaptive Precision Trainer for Myoelectric Prosthetic Users

NCT04238533
View directory record Official record
Conditions
Amputation
Interventions
eADAPT training, Conventional training
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 27, 2026, 12:41 AM EDT
Not listed Not applicable Interventional

Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP) Reduction

NCT03590249
View directory record Official record
Conditions
Glaucoma
Interventions
Osteopathic Manipulative Treatment
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

Promoting Resilience in Women With Breast Cancer

NCT06133348
View directory record Official record
Conditions
Breast Cancer
Interventions
Promoting Resilience in Stress Management Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 27, 2026, 12:41 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

NCT04671901
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma
Interventions
Romiplostim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 27, 2026, 12:41 AM EDT
Terminated Phase 3 Interventional Results available

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

NCT00731692
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
FTY720, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
25 Years to 65 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
33
States / cities
Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 3 Interventional Results available

A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

NCT06597344
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
22
States / cities
Modesto, California • Pasadena, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 27, 2026, 12:41 AM EDT
Completed Phase 4 Interventional Results available

Does Dual Therapy Hasten Antidepressant Response?

NCT00519428
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
escitalopram, bupropion extra long (XL), escitalopram + bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 27, 2026, 12:41 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Exercise in Adolescents With Insulin Resistance

NCT04154865
View directory record Official record
Conditions
Insulin Resistance
Interventions
Hypercapnia, Transcranial Doppler, Cycle ergometer, Cognitive Tests
Other · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 27, 2026, 12:41 AM EDT
Terminated Not applicable Interventional Results available

Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression

NCT02235064
View directory record Official record
Conditions
Depression, Postpartum
Interventions
Sertraline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 27, 2026, 12:41 AM EDT